Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices

Area of Science:

• Endocrinology
• Men's Health
• Geriatrics

Background:

• Hypogonadism is prevalent, particularly in aging men, often remaining undiagnosed.
• Symptoms include fatigue, reduced libido, muscle loss, and decreased bone density.
• Abdominal fat increase is linked to metabolic syndrome and type 2 diabetes.

Purpose of the Study:

• To review the evidence for testosterone replacement therapy (TRT) in managing hypogonadism.
• To address physician concerns regarding TRT and prostate cancer risk.
• To provide guidelines for diagnosing and treating symptomatic hypogonadism in primary care.

Main Methods:

• Literature review of studies on TRT efficacy and safety.
• Analysis of current clinical guidelines for hypogonadism management.
• Discussion of research gaps and future directions.

Main Results:

• TRT demonstrates strong evidence for improving body composition and sexual function.
• Evidence for TRT's impact on bone density is moderately consistent.
• TRT's effects on metabolic factors, mood, and cognition are inconsistent.
• Current data do not support concerns about TRT stimulating prostate cancer.

Conclusions:

• Primary care physicians should actively diagnose and treat symptomatic hypogonadism.
• Assess testosterone levels in men with hypogonadism symptoms or aged 40-50.
• Consider TRT for symptomatic men with serum total testosterone < 300 ng/dL, monitoring response and adverse events.